12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Selumetinib: Pilot trial data

Data from 20 evaluable patients in an open-label, U.S. pilot trial showed that twice-daily 75 mg selumetinib led to increased tumor iodine uptake in 12 patients, 8 of which achieved sufficient iodine avidity to warrant...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >